Skip to content

Evaluating Chronic Obstructive Pulmonary Disease (COPD) Patients' Treatment Compliance and Quality of Life Via Telemedicine

Treatment Compliance of Patients Diagnosed With Chronic Obstructive Pulmonary Disease And Their Quality of Life After Follow-up: Evaluation Via Telemedicine

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06477328
Enrollment
74
Registered
2024-06-27
Start date
2022-07-01
Completion date
2023-10-15
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Copd, Telehealth

Keywords

telemedicine, copd, inhaler adherence, inhaler technique

Brief summary

The Covid-19 pandemic has disrupted the follow-up and treatment processes for patients, and telemedicine has emerged as an important alternative method. Our aim was to test compare COPD Assessment Test (CAT) scores, inhaler treatment techniques and adherence between telemedicine-mediated healthcare and healthcare provided face-to-face.

Interventions

PROCEDURETelemedicine

Video calls were made with the telemedicine group.

Sponsors

Ankara Etlik City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

It is a prospective, randomized controlled, method clinical research study. Patients who were hospitalized with COPD exacerbation in the last year were included in the study and were divided into 2 groups.

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients who were diagnosed with COPD according to Global Initiative for Obstructive Lung Disease (GOLD) * GOLD spirometric grade 3-4 * At least one hospital admission in the past year * Acceptable score on the Mini-Mental State Examination * Residing in Ankara * Patient or caregiver must understand the process and be able to provide clear information * Medical records and laboratory test results must be accessible to healthcare professionals * Patient must have access to prescribed medications * Comorbidities outside of the lungs are included

Exclusion criteria

* Patients diagnosed with asthma * Patients with lung cancer * Patients with combined pulmonary fibrosis and emphysema * Patients with active infections such as pneumonia or COVID-19 * Patients being followed for COPD without spirometry * Patients with low cognitive function as determined by the Mini-Mental State Examination * Patients who do not consent to participate in the study * Patients lacking adequate social support * Patients with COPD grade 1-2 * Patients with no hospital admissions in the past year * Patients diagnosed with psychotic disorders * Patients residing outside of Ankara * Patients enrolled in inpatient or supervised outpatient rehabilitation programs * Patients unable to use telemedicine devices or without a caregiver to assist * Patients and caregivers having difficulty providing information * Patients without internet access or video call capabilities at home

Design outcomes

Primary

MeasureTime frameDescription
Inhaler adherence3 monthsAt the end of 3 months, inhaler adherence was compared. A 6-item Inhaler Adherence Scale (IAS) was used to evaluate inhaler treatment compliance. If the patient answered yes to even one of the items, they were deemed non-compliant. The questions: ''During the last 3 months; * have you at times been careless about using your inhaler or nebulizer?, * have you ever forgotten to use your inhaler or nebulizer? * have you ever stopped using your inhaler because you felt better? * have you ever stopped using your inhaler or nebulizer because you felt worse? * have you ever used your inhaler or nebulizer less than the doctor prescribed because you felt better? * have you ever used your inhaler or nebulizer more than the doctor prescribed because you felt you were having an attack?''.

Secondary

MeasureTime frameDescription
COPD Assesment Test (CAT) score3 monthsThe aim of the investigator's study is to test whether telemedicine is a safe and effective method for the follow-up of patients with advanced-stage COPD after exacerbations, to see if there is a difference in treatment adherence after 3 months of observation compared to face-to-face healthcare services, and to evaluate if there is a difference in CAT scores. The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026